Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNOMEDICS INCIMMU · Entity 145732 | Director | January 08, 2017 | January 10, 2017 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | December 22, 2016 | December 27, 2016 |
| Vaxart, Inc.VXRT · Entity 6654 | Director | June 12, 2019 | June 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNOMEDICS INC
Report date January 08, 2017 · Filed January 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2024-01-08 | Direct | 22,500 |
Reported balance
After 2017-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-08 · Grant · Acquired 22,500 · Balance 22,500 |
NOVELION THERAPEUTICS INC.
Report date December 22, 2016 · Filed December 27, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-12-22 | Direct | 9,600 |
Reported balance
After 2016-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-22 · Grant · Acquired 9,600 · Balance 9,600 F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
F2: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date.
Vaxart, Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2029-06-11 | Direct | 9,000 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 9,000 · Balance 9,000 F1: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2029-06-11 | Direct | 12,700 |
Reported balance
After 2019-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-12 · Grant · Acquired 12,700 · Balance 12,700 F2: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.).
F2: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2019 Filed Jun 14, 2019 20:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 12,700 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012100 · rdgdoc.xml · derivative · entry 2 COX GEOFFREY F · CIK 0001021014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2029-06-11 F2 · derivative.exercise_date: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012100 · rdgdoc.xml · derivative · entry 1 COX GEOFFREY F · CIK 0001021014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.). Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:30 UTC | Vaxart, Inc. AVIR · Entity 6654 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.49 Strike: $0.49 | $9,800.00 |
DisclosureSEC source: 0001437749-17-009786 · rdgdoc.xml · derivative · entry 1 COX GEOFFREY F · CIK 0001021014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,332 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 Read SEC document |
| January 08, 2017 Filed Jan 10, 2017 21:20 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Options (right to buy) · Derivative | 22,500 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001104659-17-001804 · a4.xml · derivative · entry 1 COX GEOFFREY F · CIK 0001021014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, par value $0.01 per share · 22,500 shares Expires 2024-01-08 Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 16:11 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001104659-16-163885 · a4.xml · derivative · entry 1 COX GEOFFREY F · CIK 0001021014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Shares · 9,600 shares Expires 2026-12-22 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 17:13 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001104659-16-161329 · a4.xml · derivative · entry 1 COX GEOFFREY F · CIK 0001021014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2026-12-06 F1 · derivative.exercise_price: The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant. F2 · derivative.exercise_date: The common shares underlying this stock option award were fully vested upon grant on December 6, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.